Bristol-Myers Squibb Company (BMY) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for BMY including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in BMY stock with expert risk management insights.

Risk Assessment Summary

Low overall risk profile

Low governance risk

Low market volatility (Beta < 0.8)

Governance Risk

Overall Risk Score

2/100Low

Audit Risk

4/100Low

Board Risk

5/100Low

Compensation Risk

2/100Low

Shareholder Rights Risk

2/100Low

Market Risk

Beta (5Y Monthly)

0.37Low

52-Week Change

-1.74%Low

S&P 500 52-Week Change

15.01%Very High

Short Interest Ratio

2.28Very High

Short % of Float

1.52%High

Volatility (Annualized)

33.22%Very High

Financial Risk

Total Debt

$50.99B

Enterprise Value

$136.04B

Profit Margins

10.58%Moderate

Earnings Growth (QoQ)

-22.00%Very High

Net Income to Common

$5.05B

Book Value

$8.57

Risk vs Reward Analysis

Risk Factors

Beta: 0.37

Volatility: 33.22%

Short Interest: 2.28

Potential Rewards

52-Week Change: -1.74%

Earnings Growth: -22.00%

Profit Margin: 10.58%